[EN] ANTHELMINTIC AGENTS AND THEIR USE<br/>[FR] AGENTS ANTHELMINTIQUES ET LEUR UTILISATION
申请人:INTERVET INT BV
公开号:WO2010115688A1
公开(公告)日:2010-10-14
This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.
Reaction of sulphonyl azides with unstrained olefins
作者:Rudolph A. Abramovitch、Gerald N. Knaus、Mark Pavlin、William D. Holcomb
DOI:10.1039/p19740002169
日期:——
Aromatic sulphonylazides react readily with unstrained olefins to give imines ⇌ enamines which, on hydrolysis, give the corresponding sulphonamide and ketone. In some cases, rearrangement occurs during the nitrogen elimination step. Reduction of the imines in situ with sodium borohydride leads to the arenesulphonamides in good yield.
[EN] SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF<br/>[FR] PETITES MOLÉCULES AGONISTES DE LA MUCOLIPINE 1 ET LEURS UTILISATIONS
申请人:UNIV MICHIGAN REGENTS
公开号:WO2021041866A1
公开(公告)日:2021-03-04
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.
[EN] CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30<br/>[FR] HÉTÉROCYCLES CYANO-SUBSTITUÉS PRÉSENTANT UNE ACTIVITÉ EN TANT QU'INHIBITEURS DE L'USP30
申请人:MISSION THERAPEUTICS LTD
公开号:WO2018065768A1
公开(公告)日:2018-04-12
The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. (Formula (I))